Stockscreener 앱 받기
24.92
0.65%
0.16
시간 외 거래:
24.74
-0.18
-0.72%
전일 마감가:
$24.76
열려 있는:
$24.49
하루 거래량:
8.34M
Relative Volume:
0.75
시가총액:
$9.67B
수익:
$3.14B
순이익/손실:
$-3.36B
주가수익비율:
-2.8545
EPS:
-8.73
순현금흐름:
$-4.03B
1주 성능:
-5.64%
1개월 성능:
-4.19%
6개월 성능:
+0.24%
1년 성능:
-36.93%
1일 변동 폭
$23.80
$24.99
1주일 범위
$23.80
$27.10
52주 변동 폭
$23.04
$48.92
모더나 Stock (MRNA) Company Profile
명칭
Moderna Inc
전화
(617) 714-6500
주소
325 BINNEY STREET, CAMBRIDGE
MRNA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
24.92 | 9.67B | 3.14B | -3.36B | -4.03B | -8.73 |
|
ARGX
Argen X Se Adr
|
918.53 | 57.24B | 3.06B | 1.28B | 447.35M | 19.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
435.52 | 110.12B | 11.74B | 3.68B | 3.34B | 14.19 |
|
INSM
Insmed Inc
|
201.62 | 42.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
|
ONC
Beone Medicines Ltd Adr
|
363.92 | 41.68B | 4.98B | 69.59M | 525.67M | 0.5197 |
|
REGN
Regeneron Pharmaceuticals Inc
|
725.34 | 74.02B | 14.25B | 4.58B | 3.88B | 41.77 |
모더나 Stock (MRNA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-13 | 개시 | Citigroup | Neutral |
| 2025-02-18 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2025-01-29 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-12-18 | 다운그레이드 | Argus | Buy → Hold |
| 2024-12-10 | 재개 | BofA Securities | Underperform |
| 2024-11-19 | 개시 | Berenberg | Hold |
| 2024-11-18 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2024-11-15 | 개시 | Wolfe Research | Underperform |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-09-13 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2024-09-13 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-09-13 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-08-28 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2024-08-07 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2024-08-05 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | 다운그레이드 | HSBC Securities | Hold → Reduce |
| 2024-01-02 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2023-11-29 | 개시 | Canaccord Genuity | Hold |
| 2023-11-03 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2023-11-02 | 다운그레이드 | Deutsche Bank | Hold → Sell |
| 2023-08-04 | 다운그레이드 | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2023-07-24 | 개시 | William Blair | Mkt Perform |
| 2023-07-14 | 개시 | HSBC Securities | Reduce |
| 2023-06-26 | 업그레이드 | UBS | Neutral → Buy |
| 2023-04-26 | 개시 | Guggenheim | Neutral |
| 2023-03-13 | 업그레이드 | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | 개시 | RBC Capital Mkts | Outperform |
| 2023-02-24 | 다운그레이드 | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-12-14 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | 업그레이드 | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2022-02-01 | 업그레이드 | Redburn | Sell → Neutral |
| 2022-01-26 | 업그레이드 | Deutsche Bank | Sell → Hold |
| 2022-01-21 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2022-01-21 | 개시 | UBS | Neutral |
| 2021-12-07 | 개시 | Cowen | Market Perform |
| 2021-11-09 | 개시 | Wolfe Research | Outperform |
| 2021-10-22 | 개시 | Deutsche Bank | Sell |
| 2021-10-15 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2021-08-06 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | 재확인 | Jefferies | Hold |
| 2021-02-01 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2020-12-16 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-12-16 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | 다운그레이드 | Needham | Buy → Hold |
| 2020-11-23 | 개시 | Wells Fargo | Equal Weight |
| 2020-11-17 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | 다운그레이드 | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | 개시 | SVB Leerink | Mkt Perform |
| 2020-07-20 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-07-13 | 개시 | Jefferies | Buy |
| 2020-06-30 | 개시 | Argus | Buy |
| 2020-06-08 | 개시 | Barclays | Overweight |
| 2020-04-30 | 개시 | BMO Capital Markets | Outperform |
| 2020-03-05 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | 재개 | BofA/Merrill | Buy |
| 2019-10-25 | 개시 | ROTH Capital | Buy |
| 2019-04-05 | 개시 | Chardan Capital Markets | Buy |
모두보기
모더나 주식(MRNA)의 최신 뉴스
Geode Capital Management LLC Buys 1,420,690 Shares of Moderna, Inc. $MRNA - MarketBeat
Moderna to Present at Upcoming Piper Sandler's 37th Annual Healthcare Conference on December 2, 2025 - The Joplin Globe
Moderna, Inc. $MRNA Stock Position Lifted by Letko Brosseau & Associates Inc. - MarketBeat
SG Americas Securities LLC Purchases 487,734 Shares of Moderna, Inc. $MRNA - MarketBeat
Berenberg Adjusts Price Target on Moderna to $28 From $30, Maintains Hold Rating - MarketScreener
Financial Gravity Companies Inc. Takes Position in Moderna, Inc. $MRNA - MarketBeat
Can Moderna Inc. stock hit record highs againPortfolio Value Report & Real-Time Market Trend Scan - newser.com
Candriam S.C.A. Decreases Stock Position in Moderna, Inc. $MRNA - MarketBeat
Moderna, Inc. $MRNA Shares Sold by Aviva PLC - MarketBeat
How Moderna Inc. stock benefits from tech adoptionOptions Play & Technical Pattern Alert System - newser.com
How strong is Moderna Inc. stock revenue growthJuly 2025 Closing Moves & Technical Analysis for Trade Confirmation - newser.com
How (MRNA) Movements Inform Risk Allocation Models - news.stocktradersdaily.com
Moderna (MRNA) Tops S&P 500 Short Interest List in October - GuruFocus
Mitsubishi UFJ Asset Management Co. Ltd. Reduces Stock Position in Moderna, Inc. $MRNA - MarketBeat
How Moderna Inc. stock performs during Fed tightening cyclesJuly 2025 Catalysts & Safe Capital Preservation Plans - Fundação Cultural do Pará
Resona Asset Management Co. Ltd. Reduces Holdings in Moderna, Inc. $MRNA - MarketBeat
Moderna Opens State-of-the-Art Manufacturing and R&D Facility in the UK - Lohud
Moderna Announces Phase 3 Study of Investigational Cytomegalovirus (CMV) Vaccine Did Not Meet Primary Efficacy Endpoint - York Dispatch
Moderna (MRNA) Shareholders Approve Key Proposals at Special Mee - GuruFocus
Moderna Approves Stock Option Exchange Program - TipRanks
Moderna shareholders approve stock option exchange program for employees By Investing.com - Investing.com South Africa
Moderna shareholders approve stock option exchange program for employees - Investing.com
February 2026 Options Now Available For Moderna (MRNA) - Nasdaq
Moderna (MRNA) Stock Surges Amid Partnership Talks and Strong Q3 Results - GuruFocus
What Is Going On With Moderna Stock? - Forbes
5 Insightful Analyst Questions From Moderna's Q3 Earnings Call - Finviz
CytomX Therapeutics to Present at the Jefferies London Healthcare Conference - GlobeNewswire Inc.
Tobam Purchases 55,542 Shares of Moderna, Inc. $MRNA - MarketBeat
Moderna Highlights Seasonal Flu and H5 Pandemic Flu Candidates at IDWeek 2025 - Las Cruces Sun-News
5 Insightful Analyst Questions From Moderna’s Q3 Earnings Call - Yahoo Finance
Day 5 of Gains Streak for Moderna Stock with 13% Return (vs. -36% YTD) [11/12/2025] - Trefis
Using Ichimoku Cloud for Moderna Inc. technicalsQuarterly Profit Review & Verified Momentum Watchlists - newser.com
Does Moderna Inc. fit your quant trading modelMarket Weekly Review & Weekly Top Stock Performers List - newser.com
Carisma Therapeutics Inc. SEC 10-Q Report - TradingView
Moderna Inc. recovery potential after sell offCEO Change & High Return Trade Opportunity Guides - newser.com
Moderna, Inc. Hits New 52-Week Low at USD 23.04 Amid Declining Sales - Markets Mojo
Moderna (MRNA) today — Nov. 12, 2025: Special shareholder vote on option exchange, fresh institutional filings, and live stock action - ts2.tech
Moderna (MRNA) Stock: Top Analyst Reiterates ‘Market Perform’ Rating Amid Cost-Cutting Efforts - CoinCentral
Campbell & CO Investment Adviser LLC Takes Position in Moderna, Inc. $MRNA - MarketBeat
Moderna, Inc. $MRNA Stock Position Lowered by Bank of New York Mellon Corp - MarketBeat
Acadian Asset Management LLC Purchases 477,072 Shares of Moderna, Inc. $MRNA - MarketBeat
Gilead Sciences, Moderna, Artivion, Tenet Healthcare, and Charles River Laboratories Stocks Trade Up, What You Need To Know - The Globe and Mail
Moderna (MRNA) News Today—November 11, 2025: UBS Sees 2026 Upside, Redburn Cuts PT to $36, Bernstein Stays Market Perform After Cost Cuts - ts2.tech
Moderna's Cost-Cutting, Pipeline Catalysts Set Stage for 2026 Upside, UBS Says - MarketScreener
Moderna Announces First Made-in-Canada mRNA Vaccines Delivered to Canadian Provinces and Territories - The Commercial Appeal
Moderna to Host Investor Event – Analyst Day - The Augusta Chronicle
Moderna (NASDAQ:MRNA) Price Target Cut to $21.00 by Analysts at Bank of America - MarketBeat
Rothschild & Co Redburn Adjusts Price Target on Moderna to $36 From $53, Maintains Neutral Rating - MarketScreener
Q3 Rundown: Moderna (NASDAQ:MRNA) Vs Other Therapeutics Stocks - The Globe and Mail
Moderna Reports Third Quarter 2025 Financial Results and Provides Business Updates - The Marion Star
Is it too late to sell Moderna Inc.2025 Support & Resistance & Stock Market Timing Techniques - newser.com
모더나 (MRNA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.08%
0.19%
자본화:
|
볼륨(24시간):